^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

A-319

i
Other names: A-319, A319, A 319
Company:
ITabMed
Drug class:
CD3 agonist, CD19 inhibitor
Related drugs:
4ms
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
P1, N=9, Recruiting, Wuhan Union Hospital, China | Not yet recruiting --> Recruiting
Enrollment open
|
A-319
7ms
New P1 trial
|
A-319
12ms
Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (ASH 2023)
A-319 has the same mechanism of action as that of blinatumomab, and may benefit B-NHL patients. A-319 was well tolerated in relapsed/refractory B-NHL. A-319 at the dose level of 1. 2 ug/kg/day showed encouraging disease control and warranted further clinical investigation.
Clinical
|
Blincyto (blinatumomab) • A-319